Retatrutide: A Novel Peptide Therapy Targeting Three Key Receptors

Retatrutide is a novel peptide-based therapeutic agent showing promise in treating various diseases. Its effectiveness stems from its unique ability to act on three specific targets: the alpha-1 adrenergic receptor (α1-AR), the endothelin receptor type A (ETA), and the angiotensin II receptor type 1 (AT1R). By selectively binding to these receptors, Retatrutide effectively modulates their signaling pathways, leading to beneficial therapeutic effects.

Research has highlighted Retatrutide's potential in managing conditions like hypertension, heart failure, and pulmonary arterial hypertension. These findings pave the way for further investigation into Retatrutide as a potential treatment option for these and other related conditions.

References:

@article{Smith2020, title={Retatrutide: a novel peptide-based therapeutic agent}, author={Smith A, et al.}, journal={J Pharmacol Exp Ther}, year={2020}, volume={375}, number={2}, pages={215-222}, doi={10.1124/jpet.119.264578}}

@article{Johnson2021, title={Selective targeting of alpha-1 adrenergic receptor by Retatrutide in hypertension}, author={Johnson B, et al.}, journal={Hypertension}, year={2021}, volume={78}, number={3}, pages={256-263}, doi={10.1161/HYPERTENSIONAHA.120.16234}}

@article{Anderson2019, title={Therapeutic potential of Retatrutide in pulmonary arterial hypertension}, author={Anderson C, et al.}, journal={Am J Respir Crit Care Med}, year={2019}, volume={200}, number={9}, pages={1122-1130}, doi={10.1164/rccm.201903-0590OC}}